

### REMARKS

Claims 1-46 will be prosecuted in the context of other cases, including the immediate parent case, application Serial No. 08/292,694, and thus have been canceled from this divisional application. The active claims in this case are claims 47-80.

This application is filed as a divisional application to pursue claims to processes of assaying for substances that interact with opioid receptors. Applicants submit that the claims are to a single invention drawn to a process for detecting ligands that bind to a receptor as found to exist in (Group VII) of the Restriction Requirement in copending application Serial No. 08/147,592 (Exhibit A). This determination is based on the fact that assay claims were held to be a single invention. Therefore, examination of all of the assay claims in this application as a single invention is requested.

The specification has been amended to recite the relationship with the parent case, U.S. SN 08/292,694.

Also transmitted herewith is a paper copy of the sequence listing and a Statement as Required under 37 C.F.R. § 1.821(e) and (f).

It is believed that no fee is due in addition to the enclosed filing fee. However, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the

Commissioner is authorized to deduct said fees from Arnold, White & Durkee Deposit

Account No. 01-2508/ARCD:177/WIM.

Respectfully submitted,



Mark B. Wilson  
Reg No. 37,259

ARNOLD, WHITE & DURKEE  
P.O. Box 4433  
Houston, TX 77210  
(512) 418-3000

Attorney for Applicants

Date: 5/31/95

*h:\arcd\177\pto\prelim.amd*